{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:08:31Z","timestamp":1769555311163,"version":"3.49.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Most of the 2,100 CFTR gene variants reported to date are still unknown in terms of their disease liability in Cystic Fibrosis (CF) and their molecular and cellular mechanism that leads to CFTR dysfunction. Since some rare variants may respond to currently approved modulators, characterizing their defect and response to these drugs is essential for effective treatment of people with CF (pwCF) not eligible for the current treatment. Here, we assessed how the rare variant, p.Arg334Trp, impacts on CFTR traffic and function and its response to existing CFTR modulators. To this end, we performed the forskolin-induced swelling (FIS) assay on intestinal organoids from 10 pwCF bearing the p.Arg334Trp variant in one or both alleles of the CFTR gene. In parallel, a novel p.Arg334Trp-CFTR expressing CFBE cell line was generated to characterize the variant individually. Results show that p.Arg334Trp-CFTR does not significantly affect the plasma membrane traffic of CFTR and evidences residual CFTR function. This CFTR variant is rescued by currently available CFTR modulators independently of the variant in the second allele. The study, predicting clinical benefit for CFTR modulators in pwCF with at least one p.Arg334Trp variant, demonstrates the high potential of personalized medicine through theranostics to extend the label of approved drugs for pwCF carrying rare CFTR variants. We recommend that this personalized approach should be considered for drug reimbursement policies by health insurance systems\/national health services.<\/jats:p>","DOI":"10.3389\/fmolb.2023.1155705","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T05:15:04Z","timestamp":1679030104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Personalized medicine: Function of CFTR variant p.Arg334Trp is rescued by currently available CFTR modulators"],"prefix":"10.3389","volume":"10","author":[{"given":"Violeta","family":"Railean","sequence":"first","affiliation":[]},{"given":"Cl\u00e1udia S.","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Sofia S.","family":"Ramalho","sequence":"additional","affiliation":[]},{"given":"Iris A. L.","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Jan","family":"Bartosch","sequence":"additional","affiliation":[]},{"given":"Carlos M.","family":"Farinha","sequence":"additional","affiliation":[]},{"given":"Ines","family":"Pankonien","sequence":"additional","affiliation":[]},{"given":"Margarida D.","family":"Amaral","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jcf.2018.07.001","article-title":"R560S: A class II CFTR mutation that is not rescued by current modulators","volume":"18","author":"Awatade","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"B2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ebiom.2014.12.005","article-title":"Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis","volume":"2","author":"Awatade","year":"2015","journal-title":"EBioMedicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1113\/jphysiol.2005.096669","article-title":"Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o-airway epithelial monolayers","volume":"569","author":"Bebok","year":"2005","journal-title":"J. Physiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"55159","DOI":"10.3791\/55159","article-title":"Forskolin-induced swelling in intestinal organoids: An in vitro assay for assessing drug response in cystic fibrosis patients","volume":"120","author":"Boj","year":"2017","journal-title":"JoVE"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00018-018-2896-7","article-title":"Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation","volume":"75","author":"Canato","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"B6","unstructured":"Cystic fibrosis mutation database\n            Cfmdb\n          2021"},{"key":"B7","unstructured":"Cystic fibrosis mutation database\n            Cfmdb\n          2023"},{"key":"B8","unstructured":"CFTR2 database\n            Cftr\n          2023"},{"key":"B9","doi-asserted-by":"publisher","first-page":"246ra96","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator ivacaftor abrogates pharmacological correction of \u0394F508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: From molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/354526a0","article-title":"Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation","volume":"354","author":"Dalemans","year":"1991","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B13","unstructured":"ECFS patient registry\n            Ecfs\n          2020"},{"key":"B14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1093\/bioinformatics\/btaa1073","article-title":"An open-source high-content analysis workflow for CFTR function measurements using the forskolin-induced swelling assay","volume":"36","author":"Hagemeijer","year":"2021","journal-title":"Xu J. Ed. Bioinforma."},{"key":"B16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1074\/jbc.M116.764720","article-title":"Correctors and potentiators rescue function of the truncated W1282x-cystic fibrosis transmembrane regulator (CFTR) translation product","volume":"292","author":"Haggie","year":"2017","journal-title":"J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e121159","DOI":"10.1172\/jci.insight.121159","article-title":"Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators","volume":"3","author":"Han","year":"2018","journal-title":"JCI Insight"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1073\/pnas.1215982110","article-title":"Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle","volume":"110","author":"Jih","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1146\/annurev-genom-083117-021329","article-title":"Cystic fibrosis disease modifiers: Complex genetics defines the phenotypic diversity in a monogenic disease","volume":"19","author":"O\u2019Neal","year":"2018","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17640","DOI":"10.1038\/s41598-019-54158-2","article-title":"Nanomolar-potency \u201cco-potentiator\u201d therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants","volume":"9","author":"Phuan","year":"2019","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms23010024","article-title":"Rare trafficking CFTR mutations involve distinct cellular retention machineries and require different rescuing strategies","volume":"23","author":"Ramalho","year":"2021","journal-title":"IJMS"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e86581","DOI":"10.1172\/jci.insight.86581","article-title":"Analysis of cystic fibrosis\u2013associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases","volume":"1","author":"Sabusap","year":"2016","journal-title":"JCI Insight"},{"key":"B26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/362160a0","article-title":"Mutations in CFTR associated with mild-disease-form Cl-channels with altered pore properties","volume":"362","author":"Sheppard","year":"1993","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1152\/physrev.1999.79.1.S23","article-title":"Structure and function of the CFTR chloride channel","volume":"79","author":"Sheppard","year":"1999","journal-title":"Physiol. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"B31","doi-asserted-by":"publisher","first-page":"246ra97","DOI":"10.1126\/scitranslmed.3008889","article-title":"Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression","volume":"6","author":"Veit","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jcf.2019.10.011","article-title":"Mutation-specific dual potentiators maximize rescue of CFTR gating mutants","volume":"19","author":"Veit","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B33","doi-asserted-by":"publisher","first-page":"100019","DOI":"10.1016\/j.xpro.2020.100019","article-title":"Protocol for application, standardization and validation of the forskolin-induced swelling assay in cystic fibrosis human colon organoids","volume":"1","author":"Vonk","year":"2020","journal-title":"Star. Protoc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2023.1155705\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T05:15:11Z","timestamp":1679030111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2023.1155705\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":34,"alternative-id":["10.3389\/fmolb.2023.1155705"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2023.1155705","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"article-number":"1155705"}}